Coulter Pharma, Pharma Pacific Pty. Ltd. deal

CLTR acquired from Pharma Pacific exclusive worldwide rights to 64G12, a monoclonal antibody specific to the Type I interferon receptor, and other antibodies that recognize the same receptor. 64G12 has potential utility in treating autoimmune diseases and transplantation disorders, CLTR said. CLTR will pay a $1.5 million upfront payment and up to an additional $10.25 million in license fees and milestones. Pharma Pacific is eligible for single-digit royalties. ...